Thermo Fisher Unveils Orbitrap Systems at ASMS 2026

Thermo Fisher Scientific has unveiled two new Orbitrap mass spectrometers, the Orbitrap Tribrid Apex and Orbitrap Excedion, at the American Society for Mass Spectrometry (ASMS) Conference in San Diego, running from 1 to 4 June 2026. Announced on 28 May, the platforms target both ends of the drug development continuum: deep early-discovery science on the Apex, and regulatory-grade development on the Excedion. Together they extend Thermo Fisher’s broader proteomics ecosystem strategy.

The Orbitrap Tribrid Apex is positioned as the deep-research workhorse, with five times greater sensitivity, up to 100% sequence coverage in a single experiment and results up to four times faster than the previous generation. Designed to support multiomics, structural biology, biopharmaceutical characterisation and small-molecule analysis from a single instrument, it covers more than 300 areas of research. Professor Neil Kelleher of Northwestern University’s Proteomics Center of Excellence described it as the best proteoform sequencer he has seen in 25 years.

The Orbitrap Excedion is aimed at the regulatory-grade end of the workflow, detecting three to five times more compounds in complex samples and providing the data depth needed for safety, efficacy and dosing decisions across modalities such as GLP-1 therapies, oligonucleotides and antibody-drug conjugates. Both platforms sit alongside Thermo Fisher’s Olink offering for population-scale protein analysis, deployed in initiatives such as PRECISE, an Asian biobank programme targeting biomarkers in ageing and metabolic disease. Recent acquisitions of MSAID and Proteinaceous add AI and proteoform analytics to the wider ecosystem.

What stands out commercially is not the instrument upgrade itself but the wraparound: Olink for population-scale validation, MSAID and Proteinaceous for AI-driven interpretation, and a clear positioning around GLP-1, oligonucleotide and antibody-drug conjugate modalities. The competitive bet is that mass spectrometry vendors win on integrated workflow now, not instrument specifications alone, with Bruker and Waters likely to respond in kind.